Brief: Clinuvel Pharmaceuticals Says Decision To Strategically Prioritise Three Key Clinical Programs
18/11/2024 01:09
Nov 18 (Reuters) - Clinuvel Pharmaceuticals Ltd
CUV.AX :
* DECISION TO STRATEGICALLY PRIORITISE THREE KEY CLINICAL
PROGRAMS
* PRIORITISING THREE CORE CLINICAL PROGRAMS VITILIGO
ADRENOCORTICOTROPIC HORMONE AND PORPHYRIAS
Further company coverage: CUV.AX
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist